We are live on !
Find out more
FT Options Portfolio holdings
AUM
$66.4M
Turnover
60.61%
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter Est. Return
+10.32%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
–
Cap. Flow
+$106M
Cap. Flow % of AUM
Cap. Flow %
78.55%
Top 10 Holdings %
Top 10 Hldgs %
40.45%
Holding
204
New
204
Increased
–
Reduced
–
Closed
–
Avg Time Held
Equity + Options
0
years
Top 10 Avg Time Held
Equity + Options
0
years
Top 20 Avg Time Held
Equity + Options
0
years
Avg Time Held Equity only
0
years
Top 10 Avg Time Held Equity only
0
years
Top 20 Avg Time Held Equity only
0
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$13M |
| 2 |
Chipotle Mexican Grill
CMG
|
+$8.2M |
| 3 |
CELG
Celgene Corp
CELG
|
+$6.34M |
| 4 |
Chimerix, Inc.
CMRX
|
+$5.55M |
| 5 |
DYAX
DYAX CORPORATION
DYAX
|
+$5.42M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.09% |
| 2 | Miscellaneous | 32.38% |
| 3 | Consumer Discretionary | 6.5% |
| 4 | Materials | 3.81% |
| 5 | Consumer Staples | 3.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$193B
| $12.7M | 9.35% |
+125,233
| New | +$13M |
2015 Q4
0 quarters
|
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $6.57M | 4.84% |
+54,834
| New | +$6.34M |
2015 Q4
0 quarters
|
|
|
3
Chipotle Mexican Grill
CMG
$34.8B
| $6.44M | 4.75% |
+670,650
| New | +$8.2M |
2015 Q4
0 quarters
|
|
|
DYAX
4
DELISTED
DYAX CORPORATION
DYAX
| $6.35M | 4.68% |
+168,700
| New | +$5.42M |
2015 Q4
0 quarters
|
|
5
Abbott
ABT
$179B
| $5.49M | 4.05% |
+122,300
| New | +$5.4M |
2015 Q4
0 quarters
|
|
6
Regeneron Pharmaceuticals
REGN
$82.9B
| $4.01M | 2.96% |
+7,390
| New | +$4M |
2015 Q4
0 quarters
|
|
|
7
CALL
Regeneron Pharmaceuticals
REGN
$82.9B
| $3.93M | 2.9% |
+50,700
| New | +$27.5M |
2015 Q4
0 quarters
|
|
8
CALL
Sarepta Therapeutics
SRPT
$1.87B
| $3.89M | 2.87% |
+479,400
| New | +$15.5M |
2015 Q4
0 quarters
|
|
9
Humana
HUM
$50.7B
| $2.84M | 2.1% |
+15,935
| New | +$2.8M |
2015 Q4
0 quarters
|
|
10
DuPont de Nemours
DD
$18.4B
| $2.64M | 1.95% |
+20,257
| New | +$2.6M |
2015 Q4
0 quarters
|
|
11
Viatris
VTRS
$20.7B
| $2.57M | 1.89% |
+47,500
| New | +$2.28M |
2015 Q4
0 quarters
|
|
12
United Therapeutics
UTHR
$25.2B
| $2.08M | 1.53% |
+13,267
| New | +$1.93M |
2015 Q4
0 quarters
|
|
13
Mondelez International
MDLZ
$81.4B
| $1.97M | 1.45% |
+43,897
| New | +$1.96M |
2015 Q4
0 quarters
|
|
|
LNKD
14
DELISTED
LinkedIn Corporation
LNKD
| $1.93M | 1.42% |
+8,577
| New | +$1.95M |
2015 Q4
0 quarters
|
|
15
Heron Therapeutics
HRTX
$57.5M
| $1.9M | 1.4% |
+71,049
| New | +$1.9M |
2015 Q4
0 quarters
|
|
16
IBM
IBM
$240B
| $1.88M | 1.38% |
+14,260
| New | +$1.92M |
2015 Q4
0 quarters
|
|
|
17
PUT
Regeneron Pharmaceuticals
REGN
$82.9B
| $1.87M | 1.38% |
+66,300
| New | +$35.9M |
2015 Q4
0 quarters
|
|
|
RLYP
18
DELISTED
RELYPSA INC COM
RLYP
| $1.86M | 1.37% |
+65,537
| New | +$1.41M |
2015 Q4
0 quarters
|
|
19
GameStop
GME
$12.5B
| $1.83M | 1.35% |
+260,696
| New | +$2.52M |
2015 Q4
0 quarters
|
|
|
ICPT
20
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.81M | 1.33% |
+13,400
| New | +$2.27M |
2015 Q4
0 quarters
|
|
|
AGN
21
DELISTED
Allergan plc
AGN
| $1.77M | 1.31% |
+5,669
| New | +$1.69M |
2015 Q4
0 quarters
|
|
|
POT
22
DELISTED
Potash Corp Of Saskatchewan
POT
| $1.71M | 1.26% |
+100,000
| New | +$1.99M |
2015 Q4
0 quarters
|
|
23
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $1.71M | 1.26% |
+5,213
| New | +$1.7M |
2015 Q4
0 quarters
|
|
|
24
PUT
Chipotle Mexican Grill
CMG
$34.8B
| $1.63M | 1.2% |
+1,040,000
| New | +$12.7M |
2015 Q4
0 quarters
|
|
25
Biogen
BIIB
$37B
| $1.6M | 1.18% |
+5,216
| New | +$1.5M |
2015 Q4
0 quarters
|
|
Similar funds
FIM
MKCM
MFM
VE
FT Options's Q4 2015 Portfolio in Review
Q4 2015 is the first quarter with a 13F filing on record for FT Options, which disclosed 204 positions worth $136M. Its ten largest holdings account for 40% of the portfolio.
Its largest position is Gilead Sciences: 125,233 shares worth $12.7M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, followed by Miscellaneous and Consumer Discretionary.
- FT Options's largest Q4 2015 buy was Gilead Sciences: 125,233 shares worth $12.7M.
- FT Options's ten largest holdings make up 40% of its $136M portfolio in Q4 2015.
- FT Options disclosed 204 positions in Q4 2015, its first 13F filing on record.
Based on FT Options's 13F filing for Q4 2015, filed 5 Feb 2016.